The Impact of Same-Day Antiretroviral Therapy Initiation Under the World Health Organization Treat-All Policy.


Journal

American journal of epidemiology
ISSN: 1476-6256
Titre abrégé: Am J Epidemiol
Pays: United States
ID NLM: 7910653

Informations de publication

Date de publication:
01 08 2021
Historique:
received: 30 04 2020
revised: 27 01 2021
accepted: 09 02 2021
pubmed: 13 2 2021
medline: 26 8 2021
entrez: 12 2 2021
Statut: ppublish

Résumé

Rapid initiation of antiretroviral therapy (ART) is recommended for people living with human immunodeficiency virus (HIV), with the option to start treatment on the day of diagnosis (same-day ART). However, the effect of same-day ART remains unknown in realistic public sector settings. We established a cohort of ≥16-year-old patients who initiated first-line ART under a treat-all policy in Nhlangano (Eswatini) during 2014-2016, either on the day of HIV care enrollment (same-day ART) or 1-14 days thereafter (early ART). Directed acyclic graphs, flexible parametric survival analysis, and targeted maximum likelihood estimation (TMLE) were used to estimate the effect of same-day-ART initiation on a composite unfavorable treatment outcome (loss to follow-up, death, viral failure, treatment switch). Of 1,328 patients, 839 (63.2%) initiated same-day ART. The adjusted hazard ratio of the unfavorable outcome was higher, 1.48 (95% confidence interval: 1.16, 1.89), for same-day ART compared with early ART. TMLE suggested that after 1 year, 28.9% of patients would experience the unfavorable outcome under same-day ART compared with 21.2% under early ART (difference: 7.7%; 1.3%-14.1%). This estimate was driven by loss to follow-up and varied over time, with a higher hazard during the first year after HIV care enrollment and a similar hazard thereafter. We found an increased risk with same-day ART. A limitation was that possible silent transfers that were not captured.

Identifiants

pubmed: 33576383
pii: 6133987
doi: 10.1093/aje/kwab032
pmc: PMC8327202
doi:

Substances chimiques

Anti-HIV Agents 0
Antitubercular Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1519-1532

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health.

Références

Int Health. 2018 Mar 1;10(2):78-83
pubmed: 29342259
Glob Health Action. 2017;10(1):1330915
pubmed: 28640661
PLoS Med. 2019 Jun 10;16(6):e1002822
pubmed: 31181056
PLoS One. 2013 Oct 15;8(10):e77101
pubmed: 24143205
Science. 2012 Jul 20;337(6092):298-300
pubmed: 22798404
Trop Med Int Health. 2017 Apr;22(4):375-387
pubmed: 28102610
Stat Med. 2019 Oct 30;38(24):4888-4911
pubmed: 31436859
J Acquir Immune Defic Syndr. 2014 Oct 1;67(2):e55-66
pubmed: 24977472
J Acquir Immune Defic Syndr. 2015 May 1;69(1):e24-30
pubmed: 25622060
J Int AIDS Soc. 2019 Apr;22(4):e25279
pubmed: 30993854
AIDS. 2010 Sep 10;24(14):2263-70
pubmed: 20683318
Trop Med Int Health. 2019 Jun;24(6):701-714
pubmed: 30938037
Trop Med Int Health. 2011 Oct;16(10):1297-313
pubmed: 21718394
Am J Epidemiol. 2020 Jan 31;189(1):77-78
pubmed: 31529036
Stat Med. 2011 Feb 20;30(4):377-99
pubmed: 21225900
Int J Biostat. 2010 Feb 26;6(2):Article 7
pubmed: 20305706
Stat Med. 2018 Jul 20;37(16):2530-2546
pubmed: 29687470
MMWR Morb Mortal Wkly Rep. 2018 Jun 15;67(23):663-667
pubmed: 29902168
JAMA. 2018 Mar 20;319(11):1103-1112
pubmed: 29509839
J Acquir Immune Defic Syndr. 2017 Sep 1;76(1):65-73
pubmed: 28542080
J Acquir Immune Defic Syndr. 2014 Sep 1;67(1):45-51
pubmed: 24872139
PLoS Med. 2016 May 10;13(5):e1002015
pubmed: 27163694
PLoS Med. 2016 Aug 09;13(8):e1002107
pubmed: 27504637
Trop Med Int Health. 2015 Mar;20(3):365-79
pubmed: 25418366
PLoS Med. 2017 Jul 25;14(7):e1002357
pubmed: 28742880
Pac AIDS Alert Bull. 1999;(18):15-6
pubmed: 12349391
Am J Epidemiol. 2016 Apr 15;183(8):758-64
pubmed: 26994063
Am J Epidemiol. 2019 Aug 1;188(8):1569-1577
pubmed: 31063192
J Int AIDS Soc. 2019 Jul;22(7):e25331
pubmed: 31623428
Am J Public Health. 2018 May;108(5):616-619
pubmed: 29565659
AIDS. 2018 Jan 2;32(1):17-23
pubmed: 29112073
Lancet HIV. 2019 Oct;6(10):e715-e722
pubmed: 31515166
AIDS. 2007 May 11;21(8):965-71
pubmed: 17457090
J Int AIDS Soc. 2018 Jun;21(6):e25133
pubmed: 29939483
Afr J Reprod Health. 2018 Dec;22(4):72-80
pubmed: 30632724
J Int AIDS Soc. 2019 Oct;22(10):e25401
pubmed: 31647613
Clin Infect Dis. 2018 Nov 13;67(11):1643-1652
pubmed: 29889240
Afr J AIDS Res. 2012 Mar;11(1):65-73
pubmed: 25870899
J Int AIDS Soc. 2016 Jun 15;19(1):20919
pubmed: 27312984
Afr J AIDS Res. 2019 Mar;18(1):27-37
pubmed: 30782082
J Acquir Immune Defic Syndr. 2011 Jan 1;56(1):e1-8
pubmed: 21084996
Soc Sci Med. 2017 Mar;176:52-59
pubmed: 28129547
PLoS Med. 2017 Jul 25;14(7):e1002358
pubmed: 28742819
PLoS Med. 2017 Nov 7;14(11):e1002407
pubmed: 29112692
PLoS One. 2019 Sep 6;14(9):e0222067
pubmed: 31490985
PLoS Med. 2017 Nov 7;14(11):e1002420
pubmed: 29112963

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH